News | June 24, 2014

Study Shows Promise for Speckle-tracking Echo After Transcatheter Pulmonary Valve Implantation

June 24, 2014 — Researchers have announced the results of a study that used speckle-tracking echocardiography (STE) to analyze early phase one results from the multi-center COMPASSION trial, which seeks to examine the safety and efficacy of a new option to replace dysfunctional pulmonary valves in a subset of congenital heart disease patients. Traditional echocardiography has been an excellent diagnostic tool for decades, providing a safe, cost-effective and non-invasive way to guide treatment for a wide variety of heart disease patients. Advances in ultrasound technology in recent years, such as STE, continue to expand echo’s capabilities and increase its value in modern healthcare.

“Congenital heart disease patients now survive much longer than in the past, but often experience secondary heart problems later in life, such as pulmonary valve dysfunction. The COMPASSION trial is showing promising early results, and our study suggests that speckle-tracking echocardiography (STE) may be a more sensitive tool than traditional echo or MRI to predict outcomes in these patients,” said primary investigator Shahryar M. Chowdhury, M.D. Chowdhury is an instructor of pediatric cardiology at the Medical University of South Carolina (MUSC); he and his colleagues sought to evaluate the correlation between changes in STE measures of right ventricular (RV) function and changes in measures of exercise function after Sapien transcatheter pulmonary valve (TPV) implantation.

Researchers on the study, “Changes in Speckle-Tracking Echocardiographic Measures of Right Ventricular Function Correlate with Changes in Measures of Exercise Function after Percutaneous Implantation of the Edwards Sapien Transcatheter Heart Valve in the Pulmonary Position,” included Shahryar M. Chowdhury from the Medical University of South Carolina in Charleston, S.C.; Ziyad M. Hijazi and Qi-Ling Cao from Rush University Medical Center in Chicago; John T. Fahey from Yale-New Haven Hospital in New Haven, Conn.; John F. Rhodes from Miami Children's Hospital in Miami; Saibal Kar and Raj Makkar from Cedar Sinai Medical Center in Los Angeles; Michael Mullen from The Heart Hospital in London, United Kingdom; Kyle Bilhorn and Lazar Mandinov from Edwards Lifesciences LLC in Irvine, Calif.; and Girish S. Shirali from Children’s Mercy Hospital in Kansas City, Mo..

For more information: www.asecho.org

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
GE’s blood speckle imaging (BSI) software shows the flow of blood cells’ trajectories. It is a form of blood vector flow imaging.

GE’s blood speckle imaging (BSI) software offers the ability to view a graphical representation of the blood cells’ trajectories.

News | Cardiovascular Ultrasound| September 01, 2017
Cardiologists are constantly on the lookout for new methods to examine the heart using new imaging technology advance
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Overlay Init